|
WO2021015297A1
|
|
Transgenic non-human animal capable of controlling expression of transcription factor rp58
|
|
JP2020150940A
|
|
Dengue virus vaccine
|
|
WO2020179844A1
|
|
NUCLEIC ACID CONSTRUCT ENCODING Trk FRAGMENT AND USE THEREOF
|
|
JP2020141663A
|
|
Method for producing novel tauopathy model animal
|
|
JP2021004230A
|
|
Pharmaceutical compositions for treating acute t-lymphoblastic leukemia or lymphoma or acute myeloid leukemia
|
|
WO2020100994A1
|
|
Composition for inhibiting replication of hepatitis b virus
|
|
WO2020100990A1
|
|
Strain dis-derived recombinant vaccinia virus having novel influenza virus-derived hemagglutinin protein gene
|
|
WO2020090211A1
|
|
Stabilization of double-stranded rna by cationic artificial oligosaccharide
|
|
WO2020045479A1
|
|
Antitumor agent targeting hgf-regulated tyrosine kinase substrate (hgs)
|
|
WO2019093389A1
|
|
Therapeutic agent for mental retardation or autism
|
|
CN111065400A
|
|
Anti-influenza medicine
|
|
WO2019013361A1
|
|
Hepatitis b vaccine
|
|
WO2018181298A1
|
|
Stable production and use of highly virulent enterovirus 71
|
|
JP2019122339A
|
|
Cell pharmaceuticals for treating fabry disease
|
|
JP2019089739A
|
|
Ryanodine receptor activation agent and use thereof
|
|
JP2018194451A
|
|
Specific binding reagent for detecting qualitative difference of 4 repeat tau, test method using the same, test kit, and screening method for medicine
|
|
JP2017200914A
|
|
Natural immunity-activating adjuvant using chemokine cxcl14
|
|
CN108778400A
|
|
Electroporation electrode
|
|
JP2017114855A
|
|
Diagnostic biomarker for depression or acute stress disorder and composition for treatment or prevention
|
|
JP2018093753A
|
|
Method of making non-human animal with abnormality in brain tissue, and use thereof
|
